rate < rates < rather

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 35.
[0-20] [0 - 20][0 - 35][20-34][20-40]

Ident.	Authors (with country if any)	Title
000008 (2010)	P. Roll [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H.-P. Tony [Allemagne]	Tocilizumab
000013 (2013)	Micha Levi [États-Unis] ; Susan Grange [États-Unis] ; Nicolas Frey [Suisse]	Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis
000020 (2011)	Taras Gout [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]	Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
000083 (2012)	Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon]	The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
000148 (2013)	L. Naumann [Allemagne] ; E. Feist [Allemagne] ; G.-R. Burmester [Allemagne]	Antizytokintherapie
000203 (2011)	K. Krüger [Allemagne]	Kombinationsbehandlung von Methotrexat mit DMARDs oder Biologika – Aktueller Stand
000214 (2012)	Fatma Alibaz-Oner [Turquie] ; Sibel Zehra Aydin [Turquie] ; Haner Direskeneli [Turquie]	Advances in the diagnosis, assessment and outcome of Takayasu’s arteritis
000228 (2012)	Tomoyuki Imagawa [Japon] ; Syuji Takei [Japon] ; Hiroaki Umebayashi [Japon] ; Kenichi Yamaguchi [Japon] ; Yasuhiko Itoh [Japon] ; Toshinao Kawai [Japon] ; Naomi Iwata [Japon] ; Takuji Murata [Japon] ; Ikuo Okafuji [Japon] ; Mari Miyoshi [Japon] ; Yasuhiro Onoe [Japon] ; Yoshifumi Kawano [Japon] ; Noriko Kinjo [Japon] ; Masaaki Mori [Japon] ; Neelufar Mozaffarian [États-Unis] ; Hartmut Kupper [Allemagne] ; Sourav Santra [Inde] ; Gina Patel [États-Unis] ; Shinichi Kawai [Japon] ; Shumpei Yokota [Japon]	Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
000393 (2011)	Masahiro Iwamoto [Japon] ; Sumiko Homma [Japon] ; Sachiko Onishi [Japon] ; Yasuyuki Kamata [Japon] ; Katsuya Nagatani [Japon] ; Zentaro Yamagata [Japon] ; Seiji Minota [Japon]	Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season
000433 (2013)	M. Genovese [États-Unis] ; H. Kellner [Allemagne] ; P. Durez [Belgique] ; C. E. Codding [États-Unis] ; G. Ligozio [États-Unis] ; H. B. Richards [Suisse] ; C. Escrig [Suisse] ; S. Mpofu [Suisse]	THU0111 Secukinumab treatment improves ACR50, HAQ-DI and eular remission rates in patients with rheumatoid arthritis
000475 (2013)	E. Panasyuk [Russie] ; E. Nasonov [Russie]	AB0310 Ra remission rates with tocilizumab therapy (lornet study: multicentre open-label, phase iv study of the quality of the life patient with severe/moderate ra with adding of tocilizumab to disease-modifying antirheumatic drugs therapy)
000527 (2013)	I. Ancuta ; C. Codreanu ; R. Ionescu ; M. Parvu [Roumanie] ; M. Bojinca	AB0537 Superior low disease activity and remission rates when rituximab is initiated after the first anti-TNF failure: Real life data
000540 (2013)	N. Asai ; T. Kobayakawa ; K. Saito ; T. Shioura ; Y. Yabe [Japon] ; T. Kojima ; A. Kaneko [Japon] ; N. Ishiguro	AB0564 Continuation and remission rates of tocilizumab treatment based on improvement in patient global assessment: 2-year study based on the tsurumai biologics communication registry
000572 (2013)	Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; T. Shioura ; N. Asai ; T. Kobayakawa ; K. Saito [Japon] ; N. Ishiguro	AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry
000619 (2013)	M. Can [Turquie] ; F. Alibaz-Öner [Turquie] ; S. Öner [Turquie] ; P. Atagunduz [Turquie] ; N. Inanc [Turquie] ; H. Direskeneli [Turquie]	AB0558 Accelerated infusion rates of RITUXIMAB is well-tolerated and safe in rheumatology practice: A single center experience
000636 (2013)	M. Bodro [Espagne, Australie] ; D. L. Paterson [Australie]	Listeriosis in patients receiving biologic therapies
000672 (2013)	E. Rioux [Canada] ; I. Fortin [Canada] ; M.-J. Rioux [Canada]	AB0314 The survival rates of biologics treated patients at the centre de rhumatologie de l’est du quebec : description of the real world, canadian patient cohort.
000700 (2013)	K. Minden [Allemagne] ; J. Klotsche [Allemagne] ; M. Niewerth [Allemagne] ; G. Horneff [Allemagne] ; A. Zink [Allemagne]	Biologikaregister JuMBO
000925 (2012)	P. A. Laires [Portugal] ; F. Exposto [Portugal] ; R. Mesquita [Portugal] ; A. P. Martins [Portugal] ; L. Cunha-Miranda [Portugal] ; J. E. Fonseca [Portugal]	Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
000982 (2013)	E. Nikiphorou [Royaume-Uni] ; L. Carpenter ; D. James ; P. Kiely [Royaume-Uni] ; D. Walsh ; R. Williams [Royaume-Uni] ; A. Young	OP0048 Orthopaedic interventions for RA have changed over the period 1986-2011. An evaluation of joint surgery rates and DMARD/anti-TNF treatment patterns in two UK inception cohorts
000A17 (2013)	D. Furst [États-Unis] ; K. L. Winthrop [États-Unis] ; K. A. Alexander ; A. Vashishtha ; S. F. Francom ; K. G. Saag [États-Unis]	FRI0223 Long-term targeted safety event rates in ra patients following initiation of rituximab: interim analysis from sunstone registry

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "rates" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "rates" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    rates
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021